ArticleJournal of endocrinological investigation2026
Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrediabetes is a highly prevalent and heterogeneous condition associated with an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease, and other cardiometabolic complications. Growing evidence suggests a potential role of vitamin D in glucose metabolism and diabetes prevention.
objectiveTo provide a clinically oriented interpretation of the available evidence on epidemiology, pathophysiology, clinical implications, and management of prediabetes, with a specific focus on the rationale and evidence supporting vitamin D supplementation in individuals at increased metabolic risk.
methodsA multidisciplinary panel of Italian experts in endocrinology, diabetology, and metabolic diseases reviewed current guidelines, epidemiological studies, randomized clinical trials, meta-analyses, and recent consensus statements addressing prediabetes and vitamin D.
resultsPrediabetes is a dynamic and potentially reversible condition characterized by heterogeneous trajectories of progression, persistence, or regression. Lifestyle intervention remains the cornerstone of prevention. Vitamin D deficiency is common among individuals with prediabetes and may contribute to insulin resistance, β-cell dysfunction, inflammation, and endothelial dysfunction. Clinical trials and meta-analyses suggest that vitamin D supplementation may reduce the risk of progression to T2DM and increase the likelihood of regression to normoglycemia, particularly in individuals with vitamin D deficiency or high metabolic risk, although treatment effects remain heterogeneous.
conclusionsGiven the growing clinical and public health burden of prediabetes, early identification and personalized preventive strategies are needed. Current evidence supports consideration of vitamin D supplementation as a complementary intervention in selected high-risk individuals with documented deficiency, while further studies are required to better define optimal treatment targets and patient selection criteria.
Indexed as
Identifiers
42658458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.